Goldman Sachs’s LeonaBio Inc LONA Stock Holding History

Goldman Sachs’s Portfolio LONA Stock Details LONA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,380	Closed	-$73K	–	6248
2022 Q2	$73K	Buy	+2,380	New	+$218K	﹤0.01%	5946

Other funds holding LONA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs's LONA Position: Q3 2024 in Review

Goldman Sachs sold out of LeonaBio Inc (LONA) in Q3 2024, closing a stake of 2,679 shares — an estimated $71K sold.

Goldman Sachs first reported a position in LONA in Q3 2020 and held it in 13 quarters. The position peaked at $3.32M in Q3 2020. 57 funds tracked by Wall St. Rank hold LONA as of Q3 2024.

Goldman Sachs reported no remaining LeonaBio Inc position as of Q3 2024 after selling out during the quarter.
Goldman Sachs sold 2,679 LeonaBio Inc shares in Q3 2024, an estimated $71K.
Goldman Sachs first reported a position in LeonaBio Inc in Q3 2020 and held it in 13 quarters.
Goldman Sachs's LeonaBio Inc position peaked at $3.32M in Q3 2020.
57 funds tracked by Wall St. Rank held LeonaBio Inc as of Q3 2024.

Based on Goldman Sachs's 13F filing for Q3 2024, filed 14 Nov 2024.